Product
Interferon or Glatiramer acetate
1 clinical trial
1 indication
Indication
Multiple SclerosisClinical trial
An Open-label Multicenter Study to Assess Response to COVID-19 Vaccine in Participants With Multiple Sclerosis Treated With Ofatumumab 20 mg SubcutaneouslyStatus: Completed, Estimated PCD: 2023-04-14